<DOC>
	<DOCNO>NCT01852825</DOCNO>
	<brief_summary>The purpose study assess effect various biomarkers treatment MK-8237 participant allergic rhinitis rhinoconjunctivitis . In Part 1 study healthy participant undergo nasal allergen challenge ( NAC ) house dust mite ( HDM ) extract order verify operational performance NAC associate sample collection method . Part 2 , main study , placebo control , double blind study participant HDM-induced allergic rhinitis rhinoconjunctivitis . The primary hypothesis change baseline post-allergen challenge HDM-specific Immunoglobulin G4 ( IgG4 ) Immunoglobulin E block factor ( IgE-BF ) great treatment MK-8237 treatment placebo .</brief_summary>
	<brief_title>MK-8237 ( SCH900237 ) Biomarker Study Participants With Allergic Rhinitis Rhinoconjunctivitis ( MK-8237-009 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Part 1 : healthy participant Body Mass Index ( BMI ) = &lt; 30 kg/m^2 female reproductive potential remain abstinent us two acceptable method birth control 2 week first allergen challenge 2 week last allergen challenge ; alternatively hormonal contraception may use . Part 2 : Body Mass Index ( BMI ) = &lt; 38 kg/m^2 clinical history allergic rhinitis/rhinoconjunctivitis HDM least one year , use medication relieve symptom within last year asthma , mild control asthma require regular use 12 month prior screen corticosteroid female reproductive potential remain abstinent use two acceptable method birth control 2 week first allergen challenge least 2 week last allergen challenge last dose study drug , whichever long smoke used tobacco prior 6 month , agree study Parts 1 2 : experiencing first NAC visit , symptom upper low respiratory tract infection ( viral bacterial ) participate within prior 3 month another investigational study ( included investigational drug agent ) directly associate administration study relate investigational study staff mentally legally incapacitate , significant emotional problem history clinically significant psychiatric disorder within past 5 year history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological ( include stroke chronic seizure ) abnormality diseases history cancer history significant intolerability drug food positive hepatitis B surface antigen , hepatitis C antibodies HIV major surgery lose 1 unit ( 500 mL ) blood within prior 4 week clinical history chronic sinusitis prior 2 year nasal condition ( e.g . nasal polyposis ) could confound efficacy safety assessment pregnant expect conceive study period nurse mother consumes 3 glass alcoholic beverage per day regularly us illicit drug , history drug alcohol abuse within prior 6 month Part 2 : experience allergic rhinoconjunctivitis exacerbation Screening NAC consumes excessive daily amount caffeinated beverage know history allergy , hypersensitivity intolerance investigational medicine sensitize regularly expose animal dander mold home workplace manner might interfere study opinion investigator sensitize regularly expose seasonal allergen Birch grass pollen ( sensitize season acceptable however ) history chronic urticaria and/or angioedema within prior 2 year previous immunotherapeutic treatment HDM allergen 1 month prior 3 year receive specific immunotherapy within prior 60 day history anaphylaxis cardiorespiratory symptom prior immunotherapy due unknown cause inhalant allergen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>